Supporting the future consideration of EZH2 inhibitors as immune-modulatory therapeutics is a published case study in which a metastatic chordoma patient was placed on a tazemetostat, an EZH2 inhibitor, regiment before receiving radiotherapy at the primary tumor site (56). Here, EZH2 is linked to neoplasm.